GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (BUE:GSK) » Definitions » Momentum Rank

GSK (BUE:GSK) Momentum Rank : 0 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is GSK Momentum Rank?

GSK has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


GSK Momentum Rank Related Terms

Thank you for viewing the detailed overview of GSK's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (BUE:GSK) Business Description

Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK (BUE:GSK) Headlines

From GuruFocus

Top 5 3rd Quarter Trades of Parallax Volatility Advisers, L.P.

By GuruFocus Research GuruFocus Editor 11-22-2022

GSK Enters Agreement to Acquire Aiolos Bio

By Business Wire 01-09-2024

Campbell & CO Investment Adviser LLC Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023